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Teaser This review provides an integrated roadmap for evaluating the impact of
glycosylation in the development and production of biopharmaceuticals, and the associated
challenges in glycosylation analysis and process control.
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Glycosylation of therapeutic proteins has a profound impact on their safety
and efficacy. Many factors shape the glycosylation of biotherapeutics,
ranging from expression systems and cell culture processes to downstream
purification strategies. Various analytical technologies have been developed
to address questions concerning different aspects of glycosylation.
Informatics tools are also crucial for a systematic understanding of the
glycosylation processes. Hence, an integrated approach is required to
harness glycosylation for the production of optimal and consistent
glycoprotein-based therapeutic drugs. Here, we review the latest
developments and challenges in glycosylation analysis and control in the
context of bioprocessing monoclonal antibodies.
Introduction
Glycosylation is one of the most common post-translational modifications (PTMs) of proteins,
present on more than 50% of the eukaryotic proteome [1]. Glycans impart a wide range of
functions on their protein carriers, ranging from folding and quality control in the endoplasmic
reticulum [2], intracellular and extracellular targeting [3], peptide loading onto MHC class I [4],
mediation of virus binding to host cells [5] to immune modulation of Fc receptor interactions [6].
Glycosylation of biopharmaceutical drugs has a pivotal role in their safety and efficacy by
modulating a wide range of drug properties, including immunogenicity [7], in vivo circulatory
half-life [8] and effector functions [9]. A survey of the top 20 best-selling biopharmaceutical drugs
up to 2013 shows that 11 of them are glycoproteins, out of which eight are monoclonal antibodies
(mAbs) and antibody Fc-based fusion proteins [10]. Therefore, this review will focus on mAbs
because they represent the major category of glycoprotein-based therapeutic drugs.
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WSince the approval of the first mAb product in 1986 (OKT3, which
is a murine mAb against CD3 for kidney transplant rejection thera-
py), 49 mAb-based biotherapeutics have been approved and mar-
keted in the USA and Europe [10]. As the growth engine of modern
translational biotechnology, global sales of therapeutic mAbs to-
taled nearly US$75 billion in 2013, accounting for approximately
half of the revenues accrued from all biopharmaceutical productsα-D-glucose β-D-galactose 
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FIGURE 1
Representative monosaccharide and oligosaccharide species in mammalian N-glyco
together by various glycosidic bonds. (a) Structures of monosaccharides commonly fo
galactose (Gal), mannose (Man), as well as N-acetylhexosamines (HexNAc) that includ
acids such as N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5
glycan epitope that can be found on glycoproteins expressed by non-human system
antibody drugs, including FA2 (also called G0F), FA2G1 (or G1F), FA2G2 (or G2F), FA2
terminal Gal residue can be attached to the 6-arm or the 3-arm of the core structure. (
has been reported as a major oligosaccharide species on erythropoietin (EPO). Here, w
a2,3-bond to the Gal residues. Other stereoisomers can arise from a2,6-linkage. Th[11,12]. Except for three biopharmaceuticals produced in Escherichia
coli, all other products have been glycoproteins expressed in mam-
malian cells, highlighting the importance of understanding mam-
malian glycosylation and its regulation [13].
In contrast to nucleic acids and proteins, the biosynthesis of
glycans is not directly template-driven but, rather, is a result of a
complex network of metabolic and enzymatic reactions that areα-D-mannose
osamine
uraminic acid
euraminic acid
1 (6-arm)
2
FA4G4S4
FA2G1 (3-arm)
FA2G2S2
α-L-fucose
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sylation. Glycans are oligomers of monosaccharide species that are connected
und in mammalian N-glycans, such as hexoses (Hex) that include glucose (Glc),
e N-acetylglucosamine (GlcNAc) and N-acetylgalactosamine (GalNAc), and sialic
Gc). Neu5Gc is not synthesized in humans and is considered an immunogenic
s. (b) Structure models of major N-glycan species found on recombinant IgG
G2S2 (or A2F) and Man5. Note the positional isomers of FA2G1, in which the
c) Structure model of a tetra-antennary, fully sialylated N-glycan (FA4G4S4) that
e only depict the conformation in which all four Neu5Ac residues are linked by
is also shows the complexity in detailed glycan analysis.
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Winfluenced by many factors, including the genetic profile of the
cells in which the glycoconjugates are expressed [14], epigenetics
[15] and the extracellular environment [16]. Consequently, gly-
coproteins, including biopharmaceutical products, always display
a heterogeneous set of glycans that can be influenced by the
host cell line as well as the upstream and downstream bioprocesses.
Fig. 1 shows chemical structures of common monosaccharide spe-
cies that form N-glycans, as well as structural models of oligosac-
charides typically found on antibody drugs and erythropoietin
(EPO). From a regulatory perspective, human-compatible and
consistent glycosylation is required for a safe and efficacious drug
product. This requires the drug developers to analyze the glycosyla-
tion systematically throughout the drug development and
manufacturing processes. In addition, controlling glycosylation
has been a long-standing challenge that requires a detailed under-
standing of the glycosylation pathways in cell culture processes.
This review aims to update our knowledge of the role of
glycosylation on drug properties, with a focus on IgG antibodies
and regulator requirements for glycosylation analysis. We will
then walk through the process of producing mAbs, ranging from
upstream and downstream bioprocesses to analytics and infor-
matics tools. This will cover the cell line development, and tools
for glyco-engineering host cell lines. Various upstream process
parameters have been shown to influence glycosylation and
we will provide a summary in the context of quality-by-design
(QbD) as well as a review of alternative downstream practices on
glycoform selection. State-of-the-art analytical technologies for•  Safety, efficacy, consisten
•  Biosimilarity
•  Glycoprotein purification
•  Lectin affinity
•  Boronate ligand
•  Vector design
•  Clone selection
•  Optimization and scale-up
•  CDC/ADCC
•  Combinatorial effects
•  Side effects/antigenicity
Purification strategies
Regulatory aspects
Bioprocess control
Monoclonal antibodies Cell line development
•  QbD
•  gCQAs
FIGURE 2
Developments and challenges of glycosylation analysis and control in bioprocessing
spanning the structure–function study of the drug molecule, cell line developme
regulatory approval and marketing. Each of the sectors presents significant challe
provides a summary of this review.
742 www.drugdiscoverytoday.comstructural analysis of glycosylation will be discussed. Finally, a
major bottleneck in glycosylation analysis and control lies with
the lack of informatics tools available for efficient data processing
and pathway modeling; therefore we will review the recent prog-
ress in these two areas. Fig. 2 provides an overview of the manu-
script.
Impact of glycosylation on antibody characteristics
IgG is the most abundant among the five classes of serum immu-
noglobulins. It makes up about 15–20% of serum glycoproteins. In
humans, there are four subclasses of IgG (IgG1–4), which have
differences in structure, antigen-binding characteristics as well as
in a range of interactions with cellular receptors through the Fc
region [17]. To date, most approved therapeutic antibodies are of
the IgG1 subclass which effectively initiates antibody-dependent
cell-mediated cytotoxicity (ADCC). We can learn from studies of
natural human antibodies and apply the knowledge to the devel-
opment of recombinant mAbs. The Fc region of IgG1 contains
a conserved N-glycosylation site at Asn297 in each CH2 domain.
Fig. 3 illustrates the binding of alemtuzumab (Campath1), a
humanized IgG1k mAb used to treat B cell chronic lymphocytic
leukemia (B-CLL), to its target CD52 expressed on the B cell
surface. About 20% of the circulating IgG molecules carry addi-
tional N-glycans located in their Fab region [18–21]. With the
single exception of cetuximab, which has an N-glycosylation site
in the variable region of each heavy chain (Fig. 4), all approved
therapeutic mAbs are only N-glycosylated in the Fc regioncy
•  Lectin-based selection
•  Gene editing tools
    ZFN, TALEN, CRISPR-Cas
•  Intact proteins
•  Glycopeptides
•  Released glycans
•  Automated data analysis
•  Pathway analysis
[M+2H]2+
[M+H]+
Bioinformatics
Glyco-engineering
Glyco-analytics
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. Bioprocessing for recombinant drug production involves a complex pipeline
nt, upstream and downstream processes, analytics and informatics, until
nges and opportunities for glycosylation analysis and control. This roadmap
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Campath-1H lgG1
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FA4BG4S4 glycan
FA4BG4S4 glycan
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FIGURE 3
Structure model depicting the binding of Campath-1H to CD52. The model is based on 1ce1 (PDB ID), which shows the complex of Campath-1H Fab and CD52
[259]. Color scheme is as follows: Campath-1H heavy chain (dark purple), Campath-1H light chain (light purple), glycans on Campath-1H and CD52 (blue), CD52
peptide (green), glycosylphosphotidylinositol (GPI) anchor (red), CD52 lipid carrier (orange), B cell membrane (light blue box). The glycan on CD52 is represented
by FA4BG4S4, which is a core fucosylated, tetra-antennary, fully sialylated N-glycan with a bisecting GlcNAc. Inset shows the topology of CD52. Note the relatively
small portion of the peptide in relation to the carbohydrate moiety, the GPI anchor and the lipid tail.
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W[7,22,23]. Fig. 5 shows typical glycan profiles of human serum IgG
and trastuzumab, which is a recombinant humanized IgG1 pro-
duced in Chinese hamster ovary (CHO) cells used as a targeted
therapy for HER2-positive metastatic breast cancer.
Effect of Fc region glycosylation on therapeutic antibody
characteristics
In contrast to the Fab region which recognizes antigenic epitopes,
the Fc region has limited structural diversity. The Fc region deter-
mines the function that will ensue after antigen binding. It can
recruit molecules in the innate immune system, such as C1q, as
well as cytotoxic and antigen-presenting cells via binding inter-
actions with Fcg receptors. IgGFc contains two conserved N-gly-
cosylation sites at Asn297, one on each heavy chain [24].
Variations in the structure of these glycans result in subtle changes
in structure that have a significant influence on the interaction of
IgG with the immune system (Table 1).
One of the crucial functions of Fc glycans, and indeed of
serum glycoprotein N-glycans in general [25], is to regulate
protein turnover and renewal. Circulating exoglycosidases pro-
gressively remodel glycoprotein glycans, rendering them vul-
nerable to clearance by the immune system [25]. For example, it
has been shown that the G0 glycoform of IgG, which contains
no galactose and therefore presents terminal N-acetylglucosa-
mine (GlcNAc), is bound by a C-type lectin, the mannose
receptor, and is cleared by dendritic cells and macrophages
[26,27]. Similarly, IgGs bearing high mannose-type glycansexhibit reduced serum half-life [28]. These findings have strong
implications for therapeutic antibody quality control, suggest-
ing that such glycoforms should be carefully controlled at a low
level. IgG, modified by additional sugars in the CH3 domains,
enables more-efficient binding to FcRn, the neonatal receptor,
extending the half life [29]. Fc glycans also play a part in IgG
transport, as shown by the increase in galactosylation during
pregnancy [30].
Fc region glycans can directly influence the affinity of IgGs to
Fcg receptors, either by changing the conformation of the Fc
region [31,32] or through glycan–glycan interactions [33], thus
strongly influencing their ability to recruit immune effector cells.
Fc region glycosylation helps to maintain the stability of the
molecule, and it has been shown that IgGs that have enzymatically
truncated or removed Fc glycans show reduced thermal stability,
complement binding [34,35] and impaired cell-dependent cyto-
toxic effects [36]. Furthermore, it has also been shown that the
presence of glycans containing core fucose [37] or terminal sialic
acid [38] at Asn297 reduces the affinity of IgGs to Fcg receptors. In
the case of core fucose, it has been shown that either knockdown
of the gene encoding a1,6-fucosyltransferase (Fut8) or overexpres-
sion of the gene encoding GnT-III transferase (Mgat3) results in a
lack of core fucosylation at Asn297, vastly increasing the affinity of
IgG for FcgRIIIa more than 100 times [37] and thus increasing
ADCC. Subsequent analysis of crystal structures of the Fc receptor
in complex with either the fucosylated or afucosylated Fc regions
showed that the lack of fucose allows carbohydrate–carbohydratewww.drugdiscoverytoday.com 743
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FIGURE 4
Structure model of cetuximab and the glycans attached to its Fab and Fc regions. Cetuximab is glycosylated in the Fab and Fc regions. This figure shows a model of
cetuximab with an FA2G4 glycan attached to each of the heavy chain variable regions (VH), and an FA2G1 glycan attached to each of the Fc regions. The model is
built upon 1YY8 (PDB ID), which modeled the Fab region of cetuximab. Inset shows the structure model of FA2G4, which terminates with an aGal immunogenic
epitope on each arm. Color scheme is as follows: cetuximab heavy chain (dark purple), cetuximab light chain (light purple), glycans (blue).
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Winteractions to form between the glycans of the Fc receptor and
those at Asn297, enhancing their binding affinity [33].
Fc glycans are infrequently sialylated owing to their relative
inaccessibility and their interactions with the protein surface [39],
and sophisticated methods are required to achieve a high degree of
sialylation in vitro [40]. Several studies suggest that the presence of
sialylated glycans on the Fc region reduces the ability of IgGs to
recruit effector cells via Fcg receptor binding [38,41], and that Fc
glycan sialylation is highly correlated with the presence of C-
terminal lysine [42]. Fc glycan sialylation has also been strongly
associated with anti-inflammatory properties. These studies were
initially carried out on intravenous immunoglobulin (IVIG),
which is a therapeutic product consisting of IgGs extracted from
the pooled plasma of 30 000 - 60 000 healthy donors per batch
[43]. IVIG has profound yet poorly understood anti-inflammatory
effects, and as such has been used for over 30 years to treat a wide
range of acute and chronic autoimmune and inflammatory dis-
eases. It was shown that sialic-acid-enriched fractions of IVIG had
up to tenfold higher anti-inflammatory activity compared with
unfractionated IVIG [43]. Moreover, subsequent reports showed
that the Fab regions were dispensable for this effect, and that Fc
regions were solely responsible [44]. Unsialylated IVIG was found
to interact primarily with type I Fc receptors, which includes all
Fcg receptors, whereas sialylated IVIG interacted primarily with
type II Fcg receptors, which includes lectin receptors such as
dendritic-cell-specific intercellular adhesion molecule-3-grabbing744 www.drugdiscoverytoday.comnon-integrin (DC-SIGN) [38]. This suggests that differential en-
gagement of Fc receptors on effector cells was responsible for the
observed differences in activity. These findings have not been
reproducible under all experimental conditions – a number of
researchers maintain that the anti-inflammatory properties of
IVIG are not dependent on sialylation [45–47]. Moreover, the
precise anti-inflammatory mechanism is still very much in doubt.
It has been proposed that IVIG potentiates the activation of
basophils [48] or regulatory T cells [49,50], but several studies
have shown that this is not necessarily the case [45,51].
Effect of Fab region glycosylation on antigen binding
Although the majority of IgG antibodies are modulated by gly-
cosylation in the Fc region, some 20% also contain nonconserved
N-glycosylation sites (Asn-Xaa-Ser/Thr) in the variable region.
Indeed, analyses of human and animal antibodies have shown
that variable region (mainly VH-region) carbohydrates are fre-
quently present [18–21]. A survey of human cDNA sequences
indicated that 9% of variable regions had a potential N-linked
glycosylation site [52], and other studies indicate that about 20%
of polyclonal IgGs from human serum have V-region glycosyla-
tion [53,54]. V-region glycosylation can modulate the affinity
of the antibody for its antigen, potentially either enhancing
binding strength or abolishing it completely. The net effect of
V-region glycosylation is exquisitely sensitive to the location of
the carbohydrate chain on the complementarity-determining
Drug Discovery Today  Volume 21, Number 5 May 2016 REVIEWS
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FIGURE 5
Glycan profiles of human serum IgG and trastuzumab (HerceptinW) analyzed by HILIC–UPLC. Glycans on human serum IgG and trastuzumab were released by
PNGase F treatment and labeled with 2-AB. The labeled glycans were analyzed by HILIC–UPLC with fluorescence detection. In both IgG samples, the majority of the
glycans are complex-type, neutral glycans, such as FA2 (G0F), two isomers of FA2G1 (G1F) and FA2G2 (G2F). Other truncated complex-type glycans and
afucosylated structures are also found, but at lower abundance. Oligomannose structures, most notably Man5, are typically found in recombinant IgG samples.
Their abundance in human serum IgG is much lower as a result of mannose-receptor-mediated clearance. Sialylated glycans exist in much higher abundance in
human serum IgG compared with trastuzumab, because of clones bearing Fab glycans. Other significant differences in the two IgG samples are bisecting GlcNAc
and Neu5Ac connected in a2,6-linkage, which are present in human serum IgG but not CHO-derived recombinant IgG, including trastuzumab.
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For example, a study of murine antibodies of VH subgroup IIIB
indicated that glycosylation at Asn58 in the second CDR of VH
enhanced the affinity of an antidextran antibody for its antigen
by approximately tenfold [21,55]. However, when nonglycosy-
lated, antidextran antibodies were engineered to express N-gly-
cosylation sites, it was found that glycosylation at Asn60
increased overall affinity only threefold, whereas glycosylation
at Asn54 inhibited binding to dextran. Thus, a shift in glycosyla-
tion site by only a few amino acids can turn an enhancing glycan
into an inhibitory one. To avoid any complications, during the
screening of mAbs, clones bearing Fab glycans are typically
discarded or the glycosylation sites mutated. In certain cases,
however, Fab glycosylation can be exploited to improve drug
properties. V-region glycosylation has been proposed as a way to
increase the neutralizing ability of antibodies. A recent study of
an anti-factor-VIII neutralizing antibody showed that V-region
glycosylation enhances the ability of the antibody to neutralize
factor VIII, but does not increase its binding affinity [56]. Song
et al. engineered an N-glycan into the light chain of ibalizumab, a
neutralizing antibody against HIV-1 that binds to the surface
envelope glycoprotein gp120 [57]. The Fab N-glycan refilled acavity caused by a mutation in gp120. In vitro data show the
glyco-engineered ibalizumab binds to a broad range of HIV-1
strains, including the ibalizumab-resistant mutants.
Fab glycosylation has also been proposed as a mechanism to
block self-binding sites during immune system development.
Autoantibodies on anergic B cells contained V-region glycans that
blocked antigen-binding sites capable of recognizing foreign- and
self-antigens. Reactivation of anergic B cells by foreign antigen
challenge was characterized by an increase in the germinal cell
progeny of IgMlow IgD+ anergic B cells that initially had 72% of
their antigen-binding sites blocked by V-region glycans. Following
somatic hypermutation, these binding sites were cleared of block-
ing glycans, increasing their binding affinities 100-fold [58].
In contrast to the conserved glycans in the Fc, most V-region
glycosylation sites are located on solvent-exposed loops and are
readily accessible to endogenous lectins. They tend to contain
fully processed, sialylated glycans, with a high incidence of bisect-
ing GlcNAc residues [59,60]. Intriguingly, in some cases oligoman-
nose glycans have been found within the CDR antigen-binding
regions [55], particularly in the case of follicular lymphoma
patients [61]. These glycans are accessible to C-type lectin-binding
domains in carbohydrate recognition domains such as thosewww.drugdiscoverytoday.com 745
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TABLE 1
Examples of Fc glycan on antibody properties and functions.
Fc glycan feature Impact on antibody properties and functions Refs
Asn
High mannose glycan increases serum clearance of IgG [28]
Asn
IgG G0 interacts with mannose binding protein to (i) activate complement and
(ii) facilitate serum clearance
[26,27]
Asn
IgG G2 glycoform is increased in pregnant women and umbilical cords [30]
Asn
Desialylation of intravenous immunoglobulin (IVIG) abrogates anti-inflammatory
properties in KN mice
[42]
Asn
Loss of core a(1,6) fucose on IgG results in enhanced antibody-dependent
cell-mediated cytotoxity (ADCC) activity
[33,37]
Neu5Gc-containing glycosphingolipids
Ceramide
Neu5Gc
Horse antiserum
against DT
Diphtheria Toxin Hypersensitivity in
humans
Drug Discovery Today 
FIGURE 6
The role of non-human sialic acid, Neu5Gc, in serum sickness. Injection of horse antiserum against diphtheria toxin led to hypersensitivity reactions in humans.
Antibodies were directed against H-D antigen, and were capable of agglutinating erythrocytes from a variety of mammals, including cows. Later it was found that
antibodies against H-D antigen react only with Neu5Gc-containing glycosphingolipids.
746 www.drugdiscoverytoday.com
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Wpresented by the mannose-binding lectin. The mannose glycans
were not the result of impaired glycosylation pathways because Fc
region glycosylation remained complex. V-region oligomannose
glycans do not always inhibit antigen binding [55]; instead, recent
evidence suggests that they contribute to pathological processes
by binding to lectin domains of the innate immune system such as
the mannose receptor and DC-SIGN, blocking their signaling
functions [62].
Immune reactions to antibody glycans
Humans have baseline levels of antibodies against certain non-
human glycan motifs including N-glycolylneuraminic acid
(Neu5Gc) [63] (Fig. 1) and terminal a-1,3-linked galactose (a-
gal) (Fig. 4) [7]. Their potential inclusion as PTMs on biologics
thus presents an immunogenic risk to patients. Excluding these
glycan motifs from recombinant glycoproteins is not a matter that
can be simply solved by switching production cell lines – human
cells cultured in vitro retain the ability to incorporate Neu5Gc
through the salvage pathway when supplied with exogenous
precursors to Neu5Gc in the medium [63,64] and CHO cells, which
are the workhorses of the biopharmaceutical industry, can incor-
porate Neu5Gc [65] and a-gal [66] into recombinant glycopro-
teins, thus emphasizing the need for the optimization of culture
conditions, as well as stringent quality control measures.
The production of heterophilic antibodies upon injection with
foreign serum was first described by Hanganutziu [67] and Deicher
[68] in the 1920s as part of a severe immune response termed
‘serum sickness’ (Fig. 6). These antibodies caused higher levels
of serum hemagglutination of horse, calf, sheep and rabbit ery-
throcytes, as well as complete adsorption to guinea-pig kidneyFab
Hinge
FIGURE 7
Structure model of IgE with the attached glycans. IgE has three conserved N-glycosy
Fab region of the heavy chain as well as positions 265, 371, 383 and 394 located in th
chain (light purple), glycans (blue).sediment. However, their binding targets remained undetermined
until the 1970s. Then, some early experiments with biologic drugs
were performed when anti-human thymocyte immunoglobulins
were raised in goats and injected into patients with venous immu-
nologically mediated or lymphoproliferative diseases [69]. Al-
though none of the patients experienced severe side effects, it
was found that 91% of them developed the ‘H-D antibodies’
originally described by Haganutziu and Deicher. Researchers sub-
sequently discovered that the immunological agents giving rise to
H-D antibodies were Neu5Gc-containing glycosphingolipids [70],
thus demonstrating that glycans on biologic therapeutics can
provoke systemic immune responses (Fig. 6).
Nevertheless, hypersensitivity reactions toward Neu5Gc in bio-
logics are rare. IVIG Fc fractionated with Sambucus nigra agglutinin
(SNA), a sialic-acid-binding lectin, was the primary anti-inflam-
matory component of IVIG [71], and only Fc containing two or
more sialic acids was capable of binding SNA owing to the spatial
constraints of the CH2 domains and sialic acid exposure on the
surface of the antibody [72,73]. Using ELISA and BIAcore analysis,
combined with thorough characterization of glycan profiles at
the intact antibody level with mass spectrometry (MS), our data
[41] demonstrate that the binding reactivity of the mAbs to the
anti-Neu5Gc antibody resided in the SNA-bound portion contain-
ing two or more Neu5Gc, whereas the SNA-non-bound portion
harboring only one Neu5Gc showed no reactivity. The fact that
most Neu5Gc epitopes are distributed singly on the Fc of mAbs
suggests the low potential immunogenicity of Fc Neu5Gc.
Despite increasingly sophisticated methods for biologics pro-
duction, hypersensitivity reactions still occur in 1–3% of treated
patients [7,74]. Adverse immune responses to poorly controlledFab
Fc
Drug Discovery Today 
lation sites at asparagine residues at positions 140, 168 and 218 located in the
e Fc region. Color scheme is as follows: IgE heavy chain (dark purple), IgE light
www.drugdiscoverytoday.com 747
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serious as cardiovascular failure [75]. Recent evidence indicates
that hypersensitivity to glycan immunogens is strongly mediated
by IgE antibodies [7,74,76] (Fig. 7). In a landmark study, Chung
et al. found that a high prevalence of hypersensitivity reactions to
cetuximab (Fig. 4), reported in some parts of the USA, were due to
IgE antibodies against a-gal [7], with symptoms that ranged from
transient flushing or rash to full-blown anaphylaxis. Not all
humans have sufficiently high levels of anti-a-gal IgE to elicit
hypersensitivity responses – researchers observed that the inci-
dence of either cetuximab or diet-associated a-gal hypersensitivity
were higher in South-Eastern USA relative to the northern states
[74,76]. It has been hypothesized that environmental stimuli
such as tick bites, which are prevalent in the southern states
but rarer in the north, could be responsible for regional differences
in circulating anti-a-gal IgE levels, accounting for differences in
sensitivity to cetuximab [77]. It was found that tick bites increase
the level of anti-a-gal IgE antibodies 20-fold [77], providing a neat
explanation for the observed phenomenon. Interestingly, it has
been found that the glycans in cetuximab responsible for provok-
ing hypersensitivity responses lie in the Fab region as opposed to
the Fc region because they are more accessible to IgE binding [22].
Other approved biologics such as infliximab and palivizumab,
which have been produced in murine SP2/0 and NS0 lines, also
contain appreciable amounts of a-gal, but do not provoke similar
rates of hypersensitivity reactions because they are not glycosy-
lated in the Fab region.
Regulatory perspectives on glycosylation of
therapeutic antibodies
Appropriate glycosylation is one of the critical quality attributes
(CQAs) that must be demonstrated to ensure the safety and potency
of commercial mAbs before regulatory approval. WHO guidelines
on biotherapeutics [78] and the International Conference on
Harmonization (ICH) Q6B [79] mandate state that PTMs such as
glycosylation should be identified and adequately characterized.
Thorough characterization of mAb glycan profiles and their poten-
tial impacts on safety and therapeutic efficacy are therefore an
essential part of quality control strategy. Glycan profile characteri-
zation consists of two main steps: first, complete characterization of
reference and/or conformance lots of a mAb; and, second, abbrevi-
ated tests of subsequent batches for lot release [80]. Because anti-
body glycosylation can be influenced even by subtle changes in the
manufacturing process, the abbreviated tests are often necessary to
demonstrate manufacturing consistency. However, the abbreviated
tests might not be included in the lot release assay if the sponsors
manage to prove that tight process control strategies can ensure the
consistency of the manufacturing process by adopting QbD
approaches. WHO guidelines on biotherapeutics suggest that the
selection of tests to be included in routine control programs should
be product-specific and should take into account the necessary
quality attributes; so, for mAb products in which glycosylation
has been identified as a CQA, sponsors are encouraged to include
the abbreviated test in the lot release assays. Because glycosylation is
so sensitive to environmental perturbations, therapeutic products
that are subject to manufacturing process changes must undergo
comparability studies as suggested by ICH Q5E. As part of these tests,
glycan profile analysis should be thoroughly exercised to ensure the748 www.drugdiscoverytoday.comcomparability of mAb products between, before and after process
changes have been implemented.
Biosimilars are drawing increasing attention because of the
impending ‘patent cliff’. Regulatory approval for a biosimilar
product is based on its comparability to an originator, whereas
a thorough quality comparability exercise is crucial for demon-
strating biosimilarity [81]. WHO guidelines [78] recommend the
use of the same host cell type for glycoproteins in most cases,
because glycosylation patterns vary significantly between different
host cell types [82]. European Medicines Agency (EMA) guidelines
[79] require a detailed comparison of carbohydrate structures
including the overall glycan profile, site-specific glycosylation
patterns and site occupancy. The EMA also points out that the
presence of glycosylation structures or variants not observed in the
reference medicinal product can raise concerns and would require
appropriate justification, with particular attention to non-human
structures (non-human linkages, sequences or sugars). FDA guide-
lines [83] also require the detailed comparison of glycan profiles
for biosimilars.
Cell line development
Mammalian cell lines used for manufacturing recombinant thera-
peutic proteins are derived from single cell clones producing high
amounts of product with consistent quality to meet regulatory
requirements. The process of cell line development for recombi-
nant protein production generally starts with transfecting the
mammalian host cells with plasmid vectors carrying the gene of
interest and a selection marker gene. Antibiotic-based selection is
next performed to isolate a pool of stably transfected cells with the
plasmid integrated into their genome by killing the untransfected
cells. Owing to random integration and host cell heterogeneity,
the stably transfected pool contains cells that exhibit variations in
productivity, stability and other product characteristics [84,85].
Cells with high productivity, long-term stable production and
good product quality, all of which are required for a production
cell line, are rare within a stably transfected pool. To identify cell
lines suitable for the final production, hundreds to thousands of
clones are screened through multiple stages of evaluation. Typi-
cally, a primary screen is first carried out on a small scale, for
example 96- and 24-well plates are used for productivity assess-
ment [86]. High-producing clones are identified and scaled up to
larger volumes, using shake flasks and micro bioreactors [87,88].
Although micro reactors can better mimic the subsequent, larger-
scale bioprocesses, many of the available systems are costly and
can increase the development cost significantly. Using a larger
culture volume at this stage provides sufficient material for more-
detailed characterization of cell growth, metabolism, volumetric
productivity (titer) and some product quality attributes, such as
glycosylation, in either batch or simple fed-batch cultures. The
short-list of the top-performing clones is finally characterized
again for productivity and comprehensive product quality attri-
butes in laboratory-scale bioreactors with well-controlled culture
environments to mimic the final large-scale manufacturing. In
parallel, these top-performing clones are evaluated for long-term
production stability in shake-flask cultures. Crucial product quali-
ty attributes include glycosylation profiles, charge variants, aggre-
gate levels and protein sequence variants [89,90]. Assays used for
early-stage cell line development, such as ELISA, are chosen for
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samples, whereas those used at a late stage are more complex
and are able to provide more-detailed characterizations, such as
HPLC and MS. By considering productivity, production stability
and quality requirement, a final production clone and a backup
clone are chosen for future large-scale manufacturing.
Impacts of expression vectors on glycosylation
During the past decade, R&D has focused on improving the effi-
ciency of generating cell lines with high productivity [91]. With
optimized expression vectors, high-throughput clonal selection
methods and improved media formulation, it is now possible to
generate cell lines with titers of more than 2 g/l on a routine basis.
The timeline required to generate a high-producing cell line has also
been reduced from over a year to a few months [92]. There is now a
shift from increasing productivity toward improving product quali-
ty motivated by the improved analytical tools and the rise of
biosimilars for existing blockbusters with expiring patents. Besides
obtaining high titers to reduce cost-of-goods, regulatory approval of
biosimilar products requires demonstration of comparable product
quality as the innovator drugs [93,94]. Within the list of product
characteristics, glycosylation stands out as one of the most crucial
quality attributes and the most difficult parameter to control owing
to its complex structures and sensitivity to the manufacturing
process. Many steps involved during the cell line development
process are crucial to the final product glycosylation profile. Known
factors that contribute include the host cells, the protein itself and
various cell culture environment variables [16,95]. Glycosylation
differs between different mammalian host cells and even within a
population of the same cells [96]. The choice of host cells is crucial to
determining the glycosylation profile of a product. Few studies have
looked at the impact of expression vectors on glycosylation. Differ-
ent vector designs have a direct impact on the relative amounts of
light chain and heavy chain for mAbs, affecting assembly and the
glycosylation of the product [97,98].
Promoters and other DNA regulatory elements for enhancing
recombinant protein expression could also have an impact on
glycosylation because reports have shown direct and inverse cor-
relations between protein synthesis rates and glycosylation for
different proteins [95]. Antibiotic resistance genes and metabolic
selectable genes, such as dihydrofolate reductase (DHFR) and
glutamine synthetase (GS) have been commonly used for the
generation of stably transfected cell lines [99]. Different selection
markers seem to have little effect on obtaining product with the
desired glycosylation despite their different mechanisms of action
(Yang et al., unpublished). Many studies have looked at the impact
of culture conditions and media components on glycosylation.
One conclusion drawn from these studies is that the impact of
each culture variable is cell line and protein specific [95].
Controlling glycosylation by targeted integration
As a consequence of our incomplete understanding of cell culture
parameters that affect glycosylation, the generation of cell lines
with desired glycosylation still relies on empirical clone selection,
product characterization and process development. Glycosylation
varies from clone to clone in a stably transfected pool [84].
Identifying a cell line with a desired glycan profile is challenging
using the current cell line development process. Detailed productcharacterization for a large number of cell lines at early stages of
cell line development is limited by the low throughput of the
currently available analytical tools. Moreover, the glycosylation
behavior of a cell line at an early stage might not be reflective of
that at a late stage because of changes in the cell culture media,
process and vessel types. Identifying cell lines with a desired
glycoform profile at an early stage also requires the development
of low-cost micro bioreactors to represent better the final produc-
tion process. Another attractive concept is to reuse cell lines with
well-characterized glycosylation pathways and product character-
istics. The idea involves generating a panel of master cell lines
using plasmid vectors containing homologous recognition
sequences. Besides having high productivity and stable produc-
tion, these master cells lines are chosen for their different glyco-
sylation potentials and would thus be able to produce products
with different glycan profiles. A specific master cell line able to
produce the required glycosylation could be selected for expres-
sing a specific protein through targeted integration and cassette
exchange by using either recombinase- or dsDNA-break-based
technologies [92].
Glyco-engineering host cell lines
Apart from using vector design and clonal selection to arrive at a
clone capable of producing drugs with pre-targeted glycosylation
patterns, various tools can be utilized to engineer the glycosylation
machinery of the host cell line. Alternatively, the glycans of the
protein products can be chemoenzymatically remodeled. In vitro
glyco-engineering of proteins has been demonstrated in several
cases, such as the use of a series of exoglycosidases to remove
terminal monosaccharides from b-glucocerebrosidase for the pro-
duction of Cerezyme1 [100] and, recently, the use of glycosyl-
transferases for the remodeling of IgG glycoforms to regulate the
levels of terminal galactose and sialic acid [101]. In a different
approach, Mimura et al. [102] demonstrated that, by substituting a
phenylalanine residue at position 243 of the human IgG1 Fc
region with alanine, the level of sialylated IgG glycoforms can
be increased by 5–15-fold. The concept of host cell line glyco-
engineering presents several advantages: (i) the glyco-engineered
cell lines can have restricted glycosylation capabilities, hence
reducing the overall glycan heterogeneity of their recombinant
products, this could prevent the synthesis of unfavorable glycan
structures or structures not observed on the reference materials; (ii)
it is possible for glyco-engineered cell lines to produce optimized
glycoforms, which would represent a small fraction of the total
glycoforms in the wild-type cells. This would be highly desirable
for the production of biobetter versions of therapeutic proteins,
such as afucosylated mAbs.
Lectin-based glycosylation mutant isolation
Glyco-engineering of host cell lines can be done through untar-
geted screening [103,104] or targeted, gene–genome editing tools
[105,106]. In the former approach, a common methodology is to
use cytotoxic lectins for negative selection of glycosylation
mutants [103]. Lectins can be rationally selected based on the
targeted glycosylation feature. Maackia amurensis agglutinin
(MAA) is specific for sialic acid (a2,3)Gal linkage [107,108], which
is expressed on CHO cells [109]. We previously reported the use
of MAA for the isolation of a CHO glycosylation mutant (R11, nowwww.drugdiscoverytoday.com 749
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SLC35A1 encoding the CMP-sialic-acid transporter [110]. CHO-
gmt1 was shown to contain only a basal level of sialic acids and no
significant amount of sialylated glycans was found on the recom-
binant interferon-g produced from this cell line [110]. Theoreti-
cally, MAA can also be used to isolate glycosylation mutants with
loss-of-function genetic lesions in the nonredundant steps before
sialylation along the glycan-processing pathway. Indeed, we have
isolated a CHO mutant of UDP-galactose transporter using MAA
[104] (Song et al., unpublished). Therefore, it is possible to aim for
different asialo glycan structures using MAA. One intriguing dis-
covery by Song and co-workers is that Ricinus communis agglutinin
(RCA-I) only negatively selects for mutants of N-acetylglucosami-
nyl transferase I (GnT-I) [111]. It was shown that a panel of
CHO mutants selected by RCA-I treatment all harbor mutations
in GnT-I, despite different types of genetic lesions that range from
insertion, deletion, frameshift, missense to nonsense mutations
[111]. Therefore, RCA-I-based mutant isolation strategies can ef-
fectively function as a GnT-I-targeted gene editing (i.e. knockout)
tool. Consequent to the loss-of-function mutation in GnT-I, the
mutants accumulate N-glycans at the Man5 stage, making them
desired hosts for the production of oligomannose-type glycoforms
such as b-glucocerebrosidase. Interestingly, complementing such
mutants with a functional GnT-I results in not only the restoration
of the N-glycosylation pathway but also an increase in the sialyla-
tion of N-glycans [111]. This concept was validated in a perfusion
cell culture process and demonstrated its capability of enhancing
the sialylation of recombinant erythropoietin [112].
Targeted gene editing tools
Although screening-based glycosylation mutant selection using
lectins represents a highly efficient approach, it is challenging to
select for glycosylation mutants where there exist multiple copies
of the same glycogene or functional redundancy. With the advent
of gene editing tools, such as zinc finger nuclease (ZFN), transcrip-
tion-activator-like effector nuclease (TALEN) and CRISPR-Cas9, it
is now possible to create any nonlethal knockout by targeting a
single or a set of genes for cell engineering.
ZFNs
ZFNs are unnatural nucleases consisting of arrays of zinc-finger-
binding proteins linked to the cleavage domain of an endonuclease,
typically FokI. The zinc-finger motif specifically binds the target site
on the chromosomal DNA. A pair of ZFNs binds to complementary
strands of the DNA, bringing the FokI domains to dimerization,
which in turn generates a double strand break. As the nonhomolo-
gous end-joining mechanism is activated in the cell to repair the
DNA, insertion or deletion mutations (indels) can be introduced,
which often results in functional knockout of the gene. The key to
the success rate of ZFN-mediated gene knockouts is the target site
and the corresponding zinc-finger sequence. An open-access path-
way for zinc-finger design is the modular assembly method [113], in
which each finger is designed to target a specific DNA triplicate. The
fingers that bind the 50-GNN-30 triplets are the best studied and
strong DNA-binding fingers [113–115]. Three-fingered ZFNs or four-
fingered ZFNs are commonly used. For four-fingered ZFNs, the
sequence should match the ideal target sequence which is: 50-
NNCNNCNNCNNCxxxxxxGNNGNNGNNGNN-30. The web-based
ZiFiT program provided by the Zinc Finger Consortium [ZiFiT:750 www.drugdiscoverytoday.comsoftware for engineering zinc finger proteins (V3.0)] (http://bindr.
gdcb.iastate.edu/ZiFiT/) [116] can help to identify potential sites for
ZFNs in the genes. Using ZFNs designed through the modular
assembly method, we previously demonstrated the knockout of
the Golgi GDP-fucose transporter in CHO cells [105], which were
then shown to produce fucose-free glycoproteins.
TALENs
TALENs are customized transcription-activator-like effectors
(TALEs) linked to FokI nuclease [117,118]. TALEs contain a central
DNA-binding domain with several tandem repeats of 34 amino
acids. Each repeat differs mainly in two amino acid residues at
the 12th and 13th positions, the repeat variable di-residues (RVDs).
Each TALE repeat binds one target nucleotide base as determined by
the RVDs, with the following specificity: NI = A, HD = C, NG = T,
NN = G or A [119,120]. The online tool TAL Effector Nucleotide
Targeter 2.0 is available (https://tale-nt.cac.cornell.edu/node/add/
talen) [117], to assist the identification of the targeting site. Binding
sites of TALEs always begin with a T (thymine). Different scaffolds
are available to generate TALENs with repeats typically ranging from
15 to 20 RVDs [117,118] with spacer length of 12–21 bp. For the
assembly of TALENs, Golden Gate methods [121] or high-through-
put platforms [122] can be applied.
CRISPR-Cas
The CRISPR-Cas system was first discovered in bacteria and archaea
to direct the degradation of complementary sequences present
within invading viral and plasmid DNA [123,124]. Components
of CRISPR include two noncoding RNAs: crRNA(CRISPR RNA) fused
to tracRNA and CRISPR-associated nuclease (Cas9). crRNA and
tracRNA together are referred to as sgRNA (single guide RNA)
[123,124]. Requirements for CRISPR-Cas9-based gene targeting in-
clude an initiating G, which facilitates RNA Pol III transcription at
U6 promoter region, an – NGG PAM (protospacer-adjacent motif),
followed by a 20 bp crRNA target. In theory, sgRNAs can be designed
to target any genomic sequence that has the consensus sequence
GN19NGG to induce a double-strand break [124]. This has allowed
the targeting of multiple genes simultaneously. Researchers from
the Technical University of Denmark and KAIST reported the use
of CRISPR-Cas9 to knockout Fut8, Bak and Bax in CHO cells [125].
This has opened the door to fine-tuning glycosylation and improv-
ing cell line characteristics (e.g. high productivity, resistance to cell
death and viral infection) in a rapid and cost-efficient manner. Web-
based tools are available for designing CRISPR-Cas-targeting con-
structs, for example CHOPCHOP (https://chopchop.rc.fas.harvard.
edu/) [126]. However, off-target effects are a major concern because
there is sequence homology throughout the genome [127,128].
Off-target effects that potentially impair the cell culture perfor-
mance, for example cell growth, recombinant gene expression
and quality control, should be eliminated by carefully selecting
the gene target loci and optimizing the targeting constructs.
QbD for glycosylation control in upstream bioprocesses
QbD is a conceptual framework that should be adopted in
manufacturing activity so as to build the product quality into the
process via detailed designing in the product development stage
[129]. With respect to the pharmaceutical industry, the full imple-
mentation of QbD on biologics manufacturing is more challenging
compared with that of small molecule drugs because of the com-
plexity of the biotechnology-derived products [130]. It requires a
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product quality through working within carefully outlined design
space for crucial process conditions. To apply a QbD framework, first
the desired clinical performance of the drug must be identified to
establish the quality target product profile (QTPP). Based on this
profile, related CQAs can be determined together with the process
parameters that can impact these CQAs [131]. By contrast, it is also
necessary to monitor the process parameters in a timely fashion via
process analytical technology (PAT) to ensure the previously defined
specifications for CQAs are met [130].
Glycosylation-related CQAs
Earlier, we mentioned that, where CDC is concerned, the extent
of galactosylation [132] of a mAb is considered a glycosylation-
related CQA (gCQA), whereas removal of the core fucose residue
can increase ADCC dramatically (100-fold) [9,133]. Apart from
impacting the therapeutic efficacy of the drug, the presence of
other glycan motifs, such as a1,3-linked terminal galactose, posed
a problem for the safety profile of the drug cetuximab [7]. All these
above-mentioned glycan structures can be used to construct an
array of gCQAs under the QbD framework.
Pivotal to the implementation of QbD is the pinpointing of the
gCQAs followed by monitoring and controlling them. Ludger has
proposed a systematic approach to identifying and ranking the
gCQAs via the safety and efficacy (SE) profiling and the construc-
tion of impact maps [134]. SE profiling is a visualization tool aimed
at revealing those gCQAs that alter the clinical performance of the
drug. Impact maps are mathematical graphs showing the effect of
these gCQAs on patient safety and clinical efficacy.
Upstream bioprocess parameters that affect glycosylation
To exert control over the predefined gCQAs, it is important to
understand the impact of manufacturing conditions on the glycan
distribution in the product. Apart from host cell line selection and
engineering, the conditions used in running the bioreactor have
been shown to affect the glycan profile on the biotherapies in a
product-specific manner. Among the many process parameters,
dissolved oxygen (DO) levels, culture temperatures of bioreactor
and nutrient or supplement availability are commonly controlled
and their effects on glycosylation have been studied extensively.
Some of the findings are summarized in Table 2.
High-throughput and online-ready technologies for QbD
implementation
Implementation of QbD to biologics manufacturing requires
detailed characterization of the process and thorough exploration
of the various conditions that can affect the gCQAs as described in
Table 2. Besides being able to run many conditions in micro
bioreactor systems such as AmbrTM workstation, Biolector1 and
Micro-24 MicroReactor System, a high-throughput glycan-profil-
ing platform is also needed to assess the impact of process vari-
ables on the glycan profiles quickly in a cost-effective way.
GlykoPrep [135] is such a commercial kit that allows glycan
profiling in 96-well plates using proprietary reagents and mi-
cro-cartridges. Alternative platforms for high-throughput glycan
analysis have also been reported. Doherty et al. used a protein A
immobilization strategy to achieve efficient glycan release by
PNGase F together with sample purification and concentration[136]. Beads functionalized with hydrazide groups can conjugate
with aldehyde groups from sugars enabling the purification of
glycans [137,138]. Utilizing this chemistry, Stockmann et al.
reported a novel profiling workflow with full automation [139]
and used it to profile glycans from IgG in serum samples. Instead
of analyzing the released glycan, Reusch et al. presented a work-
flow in which the IgG samples were subjected to trypsin digestion
and the resulting glycopeptides analyzed by electrospray MS
[140]. Although high-throughput technology can increase the
data points one can explore simultaneously, it is also advisable to
employ design of experiment (DoE) techniques to maximize the
information obtained from the screening data. Its application in
bioprocessing has been discussed in the review by Kumar et al.,
with case studies of applications for chromatography and refold-
ing steps [141].
Developing online methods for quick product characterization,
including glycan profiling, is also crucial for QbD implementation
because it enables real-time control over the bioreactor to inform
manufacturing operations. At Genentech, an online mAb charac-
terization strategy was proposed in which ion exchange or size
exclusion separation was followed by trapping and desalting on
reverse-phase cartridges with subsequent quadrupole time of flight
(QToF) MS analysis [142]. Major glycoforms can be identified via MS
analysis at the intact antibody level. Primack et al. from Amgen used
a microchip-based CE method to profile the glycans from antibody
cell culture [143]. The glycans were released from the purified mAbs
and sent for CE analysis on the Caliper Labchip GXII Microchip-CE
platform. M5, G0, G0F, G1F and G2F can be identified from the
electropherogram. Agilent’s multilayered microfluidic chip provid-
ed an integrated system for glycan release, clean-up, PGC-based
separation and integrated electrospray into MS [144]. Only 100 ng
of mAb was needed for the assay, and the whole analysis including
sample preparation can be done within 10 min.
Quantitative models for predicting N-glycosylation in cell
cultures
Although real-time monitoring of the detailed glycoforms dur-
ing the biomanufacturing process still remains a challenge, now
that the CHO cell genome has been sequenced [145] a system-
atic understanding of the pathways can offer some help in our
ability to understand and eventually predict the effects of
process changes on glycan profiles of the final product. Initial
computational models [146–148] approximated the Golgi appa-
ratus as a series of continuously stirred tank reactors (CSTRs)
where reactions are centered on glycosyltransferases to generate
more than 7500 potential glycan structures. Hossler et al. started
to adopt the Golgi maturation model and used plug flow reac-
tors in series to mimic the change in enzyme concentrations
along the Golgi apparatus [149]. Follow-up models were devel-
oped to look into the microheterogeneity of antibody glycosyl-
ation specifically, and particular attention was paid to the
nucleotide sugar donor (NSD) level to link glycosylation to
cellular metabolism [150,151].
Downstream bioprocessing of glycoproteins
In common with other biopharmaceuticals, therapeutic glycopro-
teins typically require exceptional purity and constant potency,
making effective and efficient downstream processing a crucialwww.drugdiscoverytoday.com 751
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TABLE 2
Effects of cell culture conditions of on glycosylation.
Conditions in
the bioreactor
Effect on the bioprocess or product Mechanism of action
Dissolved oxygen
tension (DOT)
For erythropoietin (EPO)-Fc produced in CHO, the sialylation
fluctuated between 11 and 14 mol sialic acid/mol EPO-Fc for
10–90% DOT, but dropped drastically at 100% DOT
Mechanism not defined [106]
For human follicle-stimulating hormone produced in CHO,
maximum sialylation at 100% DOT
Mechanism not defined [107]
For IgG1 produced in murine hybridoma cells, reduced DOT
resulted in reduced galactosylation
Not clear. One suggested reason is that it is due to decreased
UDP-Gal transport from the cytosol to Golgi [108]
pH/[NH4
+] For tumor necrosis factor receptor (TNFR)-IgG produced in
CHO, as [NH4
+] increased from 1 to 15 mM terminal
galactosylation and sialylation decreased up to 40%
It was hypothesized that [NH4
+] inhibits SiaT and GalT by
increasing the pH of the trans-Golgi compartment [109]
For EPO produced in CHO, at 10 mM NH4Cl, a reduction in
sialylation was observed for both N- and O-linked glycans
It might be ascribed to an increase in intra-Golgi pH. Another
possibility of increase in extracellular sialidase activity was
ruled out [110]
For IgG3 produced in mouse hybridoma cell line, total sialic
acid content is in the order of pH 7.2 > HEPES > pH 7.4 > pH
6.9; highest relative amount of agalacto structures were
found in pH 7.2 and pH 6.9 culture
Mechanism not defined [111]
For interleukin (IL)-2 produced in BHK-21, at 15 mM NH4Cl
there is a significant increase of tri- and tetra-antennary
glycans
The increase in complexity is considered to be brought by
the increased levels of intracellular UDP-GlcNAc/GalNAc in
the presence of high NH3/NH4
+ [112]
Temperature For EPO produced in CHO, temperature range of 25–37 8C
was used. The proportion of tetra-antennary structures
reached maximum at 32 8C. The proportion of tetrasialylated
glycans stayed roughly the same between 37 and 32 8C, but
decreased by 24.4% when culture temperature dropped to
25 8C
The author found that high specific EPO productivity at high
temperature is probably not the cause instead the observed
difference might be attributed to enzyme activity reaching
optimum between 32 and 37 8C [113]
For EPO-Fc produced in CHO, when culture temperature was
shifted from 37 to 30 8C there was a reduction of sialylation
by 40%
Mechanism not defined [114]
Nutrient
supplement
For interferon (IFN)-g produced in CHO, lipoprotein-
supplemented medium helps to maintain the extent of
glycosylation with time in batch culture
Mechanism not defined [115]
For monoclonal antibodies (mAbs) produced in murine
hybridoma, higher glycan microheterogneity was found for
culture supplemented with fetal bovine serum (FBS); G0
content was higher with FBS supplementation; with FBS
addition, increase in sialylation and decrease in fucosylation
were also observed
It was mentioned that extracellular b-galactosidase activity
increases threefold for serum-free medium [116]
For IFN-g produced in CHO, glucose limitation and glutamine
limitation can reduce the site occupancy of the product
Nucleotide triphosphate depletion was thought to be the
cause of decrease site occupancy during glucose limitation.
Whereas glutamine limitation influenced glycosylation by
reducing amino sugar formation [117]
For chimeric heavy chain antibody (EG2) produced in CHO,
deprivation of glucose resulted in a 45% nonglycosylated
mAb fraction
When glucose is not sufficient, it will be preferentially used
for energy metabolism rather than replenishing the
nucleotide sugar pool that serves as the precursor to
glycosylation [118]
For IFN-g produced in CHO, very low glutamine (<0.1 mM) or
glucose (<0.7 mM) can lead to decrease of sialylation and
increase of hybrid and high-mannose glycans
Glutamine limitation can limit the formation of UDP-GlcNAc
by limiting amino sugar formation. This will in turn decrease
the formation of CMP-NeuAC [119]
For human chorionic gonadotrophin (HCG) produced in CHO,
in continuous culture setting, glutamine supplement
concentration was alternating between 0 mM and 8 mM for
90 days. 15 glycan structures from HCG were profiled at
various time points. Reduction in sialylation and antennarity
of HCG was observed with a decrease in glutamine coupled
with low glycolytic flux
From metabolic flux analysis and monitoring of nucleotide
sugar metabolism, it was suggested that high glutamine
concentration contributes to the accumulation of UDP-
GlcNAc and UDP-GalNAc which are required by
glycotransferases when adding new glycan chains to
biantennary structures. UDP-GlcNAc is also a necessary
precursor for the synthesis of CMP-NeuAc and hence impacts
sialylation [120]
For IgG produced in human cell line rF2N78, aglycosylated
antibody was produced when glucose was depleted from
the medium. Alycosylated antibody was not observed with
glucose feedng in fed-batch culture
Glucose capping on oligosaccharide is a key step in the
oligosaccharide recognition by the oligosacchryl tranferase,
which eventually leads to glycosylation at the asparagine site
[121]
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Wstep in the overall production process [152]. The generic process
for the recovery and purification of glycoproteins produced by
animal cell culture consists of successive capture, purification and
polishing steps, each comprising one or more procedures [153].
Protein A chromatography is the industry standard for commer-
cial-scale purification of mAb products. In the research environ-
ment, however, the capture step might employ lectin or boronate
affinity chromatography by selectively capturing the glycan com-
ponent. Purification and polishing are conducted with ion ex-
change and hydrophobic interaction chromatography to remove
aggregates, endotoxins, host cell proteins and DNA [154]. In
addition, some intermediate, nonchromatographic purifications
are also employed such as ultra- and dia-filtraton as well as
clarification techniques [155–157].
Lectin-based purification
Lectins are carbohydrate-binding proteins and have been widely
used to identify and isolate glycoproteins, glycopeptides, glycoli-
pids and oligosaccharides [158]. Lectins are found in plants and
animals, and have specificity for certain types of carbohydrate
residues. The most common lectins currently being used are
concanavalin A (Con A),which has specificity for a-D-mannose,
a-D-glucose residues and bi-antennary N-glycans [159], wheat-
germ agglutinin (WGA) with specificity for N-acetylglucosamine
residues [160], jacalin with specificity for galactose and mannose
residues [161], MAA and SNA, with specificities for Sia a2,3- and
a2,3-linked Gal, respectively [108]. Additional lectins are available
for binding to less common glycans. EPO, influenza vaccine and
other therapeutic glycoproteins can be purified using lectin affini-
ty chromatography [162,163]. However, as a class of biological
receptors, lectins have significant disadvantages including multi-
ple specificities, expensive purification costs, degradation during
standard sterilization and subsequent contamination of the end-
product as a result of ligand leaching.
Boronate-based purification
Since 1970, boronate columns have been exploited as less-expen-
sive and more-stable alternatives to lectins for the separation of
glycoproteins. The most commonly used boronate adsorbent is m-
aminophenylboronic acid agarose, which has been investigated
for the specific capture of glycoproteins from protein mixtures;
successful applications include the selective capture of IgG from
CHO cell supernatant [164], EPO from mammalian cell cultures
[165], ovalbumin from egg white [166], ovalbumin and ribonucle-
ase B (RNase B) from BSA [167], horseradish peroxidase (HRP) from
BSA, RNase B from myoglobin [168] and glycopeptides from non-
glycopeptides of digested HRP [169], among others. However, to
form stable cyclic esters between m-aminophenylboronic acid and
cis-diol compounds, alkaline conditions are required (pH  8.5)
[170]. It is not desirable to perform glycoprotein separation at such
high pH, because it can lead to the degradation of some labile
glycoproteins. To address the challenge, new boronate ligands that
can work at physiological conditions have been studied and
applied to the enrichment of glycoproteins [171,172].
Future needs for cost-efficient glycoform separation technologies
Unlike protein synthesis, which is under genetic control, glycan
synthesis is not directly template-mediated and thus glycoproteinsare typically expressed and marketed as populations of glycoforms
with potentially different biological properties [173]. The different
properties associated with each glycoform within the resulting
heterogeneous mixture present regulatory difficulties for thera-
peutic glycoproteins and also problems in determining exact
structure–activity relationships [173]. It is therefore important
to the biopharmaceutical industry to be able to produce products
with homogeneous glycoforms that can confer significant and
predictable therapeutic advantages. However, protein production
costs remain extremely high, with downstream processing consti-
tuting a substantial proportion (50–80%) of the overall cost [174].
It is expected that the development of new purification techniques
exploiting inexpensive, specific, effective, robust and easy-to-use
methods and materials will shape the future of glycoprotein
purification [175].
Technologies for glycosylation analysis
The absence of a direct genetic blueprint and the nonlinear
structures of glycans makes glycosylation analysis one of the most
challenging physicochemical characterizations of biopharmaceu-
tical products. The past two decades have seen tremendous devel-
opments in analytical instruments and knowledge of protein
glycosylation. It has now become a consensus that, in glycosyla-
tion analysis, the question dictates the exact approach [176].
Broadly speaking, glycosylation analysis of therapeutic proteins
can be performed at three levels, namely, intact protein, glyco-
peptide and released glycans, as illustrated in Fig. 8.
Intact glycoprotein analysis
There are a variety of analytical methods for characterization at the
intact protein level, which include chromatography, electropho-
resis, MS and other spectroscopic techniques. Owing to the super-
ior resolution, MS has become a crucial analytical tool to
characterize mAbs in many phases of the developmental process.
Through top-down approaches that deal with intact protein sam-
ples, information such as molecular weight, and major modifica-
tions such as glycosylation, can be obtained. In top-down analysis,
high-resolution mass analyzers are required, including ToF, Orbi-
trap and Fourier transform ion cyclotron resonance (FT-ICR)
instruments to resolve small mass differences [177]. Valeja et al.
showed that it is possible to achieve isotopic resolution through
the use of FT-ICR for the analysis of intact IgG1 [178]. However,
even with the use of FT-ICR, it is still challenging to resolve
small mass changes such as deamidation, dehydration and oxida-
tion [179]. In addition, FT-ICR is not a very commonly used
instrument in the biopharmaceutical environment because of
the tedious maintenance of the superconducting magnets and
its high price.
Intact protein samples for top-level analysis usually undergo an
online or offline separation step (e.g. LC, CE) before ionization by
electrospray (ESI) or matrix-assisted laser desorption (MALDI) MS
[180]. Although direct infusion of the intact mAbs is also possible,
a desalting step is often required to obtain high-quality spectra
with fewer salt adducts and better ionization efficiency. Using an
ESI source, intact IgG samples can form quasi-molecular ions with
high charge state (z in the range of 20–60) and the resulting m/z
values in the range of 2000–5000 amu, which can be measured by
many types of mass analyzers. By contrast, an intact IgG samplewww.drugdiscoverytoday.com 753
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FIGURE 8
The top, middle and bottom levels of glycosylation analysis. Depending on the exact objective, glycosylation analysis can be performed at different levels. This picture
depicts the top, middle and bottom levels of glycosylation analysis in analogy to protein analysis, using monoclonal antibody drugs as an example. In top-level analysis,
the intact glycoprotein is analyzed by mass spectrometry either through direct infusion or preceded by a separation system such as a liquid chromatograph. The high-
resolution accurate mass, (HR/AM) mass spectrometer measures, to high precision, a series of mass:charge ratios (m/z) of the IgG under question, which arise from a
consecutive series of charge states. Using a computer-assisted deconvolution algorithm, neutral mass (molecular weight) of the IgG can be derived. Typically for
monoclonal IgG molecules, severalneuralmassesare revealed after deconvolution thatcorrespondtodifferent glycoformsand/or proteoforms. Byexaminingthe mass
difference among the different forms of the intact IgG, and comparing with the mass(es) of the deglycosylated IgG, each neutral mass can be assigned to a particular
glycoform or proteoform. Here, we show our data on a monoclonal antibody product, showingmainly G0F/G0F glycoform. The top-level analysis offers a unique insight
into the pairing of glycans on the two heavy chains of an IgG molecule. We refer intact glycopeptide analysis as middle-level analysis. This typically involves proteolytic
digestion of the glycoprotein, followed by LC–MS/MS analysis. Fragmentation of the glycan moiety can produce rich information on the composition and arrangement
of the monosaccharide building blocks on the glycan. Middle-level analysis serves to answer the question of glycosylation microheterogeneity because it supports the
elucidation of the carrier peptide sequence in addition to glycan compositional analysis. This is often necessary in the case of multiple glycosylation sites on a protein.
Peptide-specific fragmentation is now better supported with the development of new ion fragmentation techniques, such as electron-transfer dissociation (ETD). In
bottom-levelanalysis ofglycosylation,glycans are cleaved off the carrierprotein and analyzed asa pool. Popular techniques for released glycan analysis involve tagging
the glycans with a fluorescent dye and separating the labeled glycans by LC–capillary electrophoresis (CE), with or without introducing them to a mass spectrometer.
Away from the carrier proteins or peptides that often dominate the overall physicochemical properties of the glycoconjugate, bottom-level analysis of released glycans
shows high sensitivity and quantitation power, which supports in-depth characterization of glycans including their compositions, sequences and glycosidic linkages.
However, once detached from the protein backbone, the information on the local context, such as site of attachment and pairing, is lost.
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tions, which diminishes the resolution and mass accuracy [181].
High mass resolution required in the analysis of top-down
analysis of intact monoclonal IgG antibodies without the use of
FT-ICR is also achievable using hybrid QToF [182] or hybrid linear
quadrupole ion trap–Orbitrap MS [183]. Through the use of the
Orbitrap analyzer, Bondarenko et al. employed three different
delivery methods: (i) direct nano-ESI infusion; (ii) step-elution;
and (iii) online reversed-phase HPLC, to determine major glyco-
forms with different numbers of terminal galactose (162 Da)754 www.drugdiscoverytoday.comresidues accurately in the intact IgG from the deconvoluted mass
spectra [184]. The analysis of intact mAbs represents a fast and
robust way to determine batch-to-batch consistency (analysis time
is a few minutes), in which minimal sample preparation is re-
quired. However, the detection of minor glycoforms remains a
challenge. In a similar fashion, antibody subunits or fragments can
be analyzed by middle-down strategies based on high-resolution-
accurate MS platforms coupled with appropriate separation fronts.
Different chemical and enzymatic approaches, such as reduction
of inter-chain disulfide bonds by reducing agents and specific
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simultaneous elucidation of glycoforms and other PTMs located in
the heavy chain of antibody molecules [185].
Glycopeptide analysis
The analysis of glycosylation microheterogeneity is essential to
understanding the site-specific contribution of glycan structures
on the safety and efficacy of drug products. Typical of bottom-up
approaches, a glycoprotein sample is first digested by proteolytic
enzymes, such as trypsin, then analyzed by separation techniques
(e.g. HPLC or CE) or MS. MALDI or ESI are often used as the soft
ionization methods to preserve the structural integrity of glyco-
peptides. The applicability of MALDI for high-throughput analysis
has been recently demonstrated in a study profiling the N-glycans
of the Fc region in IgG through glycopeptide analysis [186]. Such
methods could be implemented when analyzing large batches of
samples such as during process development or batch-to-batch
monitoring. Competitive ion suppression (glycopeptides vs pep-
tides) is often a major hindrance resulting from the complexity of
enzymatic digestions of the glycoprotein. Therefore, various meth-
ods for glycopeptide enrichment have been developed, such as the
use of size exclusion chromatography [187] and hydrophilic inter-
action chromatography with cellulose or sepharose [188]. Alter-
natively, an online hydrophilic liquid chromatography (HILIC)
separation that is coupled to nano-ESI–MS or UPLC–MS could also
be employed based on the hydrophilicity of the glycopeptides
[189–192].
Tandem mass spectrometry (MS/MS) is required to elucidate the
sequences of the carrier peptide, the glycan composition and the
site of glycan attachment. Collision-induced dissociation (CID),
such as high-energy C-trap dissociation (HCD) in Orbitrap instru-
ments, generates distinct product ions of peptide with the inner-
most GlcNAc residue of an N-glycan (i.e. the y1 ion), which can be
used to determine the N-glycosylation site [193]. Using database
searching for bottom-up proteomic measurements with the core
GlcNAc as a variable modification, the identity of the glycopeptide
together with the N-glycosylation site can be determined. The
presence of glycan oxonium ions (e.g. b ions at m/z = 204 for
HexNAc, and 366 for HexNAc + Hex, and 276 for dehydrated
Neu5Ac) at low mass range are also used as a marker for glycosyla-
tion. CID fragmentation of glycopeptides almost exclusively
results in the cleavage of glycans from the peptide backbone to
generate a series of y-fragment ions related to glycosidic cleavages,
at higher mass range [193,194]. Thus, CID is a suitable technique
for determining glycan compositions and even structures based on
the glycan sequence tag. The use of QToF–MS/MS to obtain CID
fragment-type ions has been widely used in the analysis of sialo-
and asialo-complex-type N-glycopeptides to obtain information
on the glycan moiety [195]. In more recent papers, information on
peptide sequence, glycan moiety and glycosylation site were
obtained within one analytical run with the use of alternating
high and low collision energy (MSE) [182]. Precautionary measures
have to be taken when analyzing the glycan moiety from the CID
spectra of glycopeptides, because of the possibility of fucose rear-
rangement, which could be mistaken for b- and y-ions [196,197].
Newer fragmentation techniques, such as electron-activated
dissociation (ExD), electron capture dissociation (ECD) and elec-
tron transfer dissociation (ETD), preserve labile PTMs suchas glycosylation [198–200] but selectively fragment the peptide
backbone, allowing the determination of peptide sequence and
N-glycan attachment sites through the generation of peptide
fragment ions and a mass-shift resulting from the attached glycan
[201]. ExD complements CID and the two techniques can be
combined to obtain information about the glycopeptide. Analysis
of the glycopeptide can be done on MALDI–MS/MS to provide
information of the peptide and glycan moiety. Depending on the
configuration of the instruments, various distinct fragment ions
can be observed. However, ExD only works efficiently for ions of
high charge states and in the low m/z range; one way to circum-
vent this would be the addition of m-nitrobenzyl alcohol into the
mobile phase to increase the charge-state of glycopeptides [202].
With the use of MALDI–ToF/ToF, cleavage of the side-chain amide
bond of glycosylated asparagine usually occurs, giving a diagnostic
peak together with b- and y-ions from the peptide backbone.
Advances in instrumentation, particularly fragmentation techni-
ques, now relocate the major bottleneck in glycopeptide analysis
to the software solutions that are needed for high-throughput,
high-confidence MS interpretation. This point will be discussed
below.
Analysis of released glycans
The determination of monosaccharide composition, glycosidic
linkage and relative abundance of a glycan in a mixture (Fig. 1)
is highly relevant to understanding the safety, efficacy and batch-
to-batch consistency of glycoprotein therapeutics. Depending on
the exact analytical requirement, glycans released from a protein
carrier can be profiled, characterized and/or analyzed in-depth.
Glycan analysis poses significant technical challenges owing to the
lack of a chromophore in the natural carbohydrate molecules and
structural heterogeneity caused by anomericity, linkage positions
and configurations. Therefore, released glycans are often fluores-
cently labeled for sensitive detection [203] or derivatized to
improve the ionization efficiency and minimize in-source or
post-source decay in MS analysis [204]. Over the past two decades,
high-performance tools have been developed for structural analy-
sis of released glycans, mainly based on high-resolution separa-
tions (e.g. HPLC/UPLC, CE) and MS [176].
Liquid chromatography
HPLC-based glycan analytical workflows typically involve fluores-
cent labeling of glycan species. Several fluorescent tags have been
attached to N-glycans, such as 2-aminobenzamide (2-AB) and 2-
aminobenzoic acid (2-AA) [203]. Recently, two new fluorescent
labels for N-glycans have been reported, namely RapiFluor-MSTM
(RFMS) [205] and 6-aminoquinolyl-N-hydroxysuccinimidyl carba-
mate (AQC) [206], both based on the rapid reaction of glycosyla-
mine with N-hydroxysuccinimide-activated carbamate. The use
of UPLC has greatly reduced the amount of time required for data
collection and gives good resolution because it can withstand
higher pressures as a result of the smaller particle size (often
less than 2 mm), in comparison to HPLC. UPLC has become
the method of choice for efficient separation owing to shorter
separation time, better resolution, particularly of arm-specific
isomers, and relatively easy coupling to mass spectrometers
[207,208]. The use of HILIC as a separation mode and a fluores-
cently labeled dextran ladder as an external calibration standard
has enabled fast and highly reproducible glycan analyses acrosswww.drugdiscoverytoday.com 755
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mental database (i.e. Glycobase) contains normalized retention
time values (GU values) for a wide collection of glycan species
analyzed by HILIC–HPLC/UPLC, in addition to data collected
from RP–HPLC and CE–LIF platforms [211]. Coupled with exogly-
cosidase array digestions (Fig. 9), this has enabled relatively straight-
forward structural assignment [211,212]. By specifically removing
terminal monosaccharides of particular linkages, exoglycosidase
array digestion also helps identify co-eluting glycan species
(Fig. 9). Recently, a robotized and low-cost N-glycan analysis
platform to profile IgG was developed. The platform includes
features from rapid IgG purification from cell culture through affini-
ty binding to the labeling of released glycans in a 96- or 384-well
format with excellent reproducibility based on UPLC analysis [139].
The development of high-throughput platforms for the analysisRetention time [min]
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FIGURE 9
Determining monosaccharide compositions and linkages using exoglycosidase arra
species, an array ofexoglycosidases can be used to remove monosaccharide building b
undigested and digested glycan samples are analyzed by HILIC–UPLC. By following the
can deduce the sequence and linkages of monosaccharides of the glycan in question
times, namely A2G2S1 (boxed in red) and Man7 (boxed in green), in the undigested c
ureafaciens sialidase (ABS), bovine testes b-galactosidase (BTG), bovine kidney alpha-fu
of the exoglycosidase, co-eluting glycans can be separated apart. In this case, treatm
(indicated by the red arrow) which is characteristic of a Neu5Ac residue. BKF treatment
fucosylated glycans in this sample. A further digestion using BTG shifted the A2G1 str
two Gal residues. Finally, a further digestion by GUH shifted the A2 forward by 1 GU t
Throughout the digestion, Man7 remained at the original elution envelope (indicat
deconvolution of co-elution structures and in-depth analysis of glycans in a highly 
756 www.drugdiscoverytoday.comof IgGs will prove to be invaluable for clonal selection of mAb
drugs, development of biosimilar candidates and genome-wide
association studies [14,213]. An added advantage in using UPLC
is its ease of coupling with MS technologies, which can be used as
an orthogonal method for glycan analysis. One commercially avail-
able LC–MS technology for detailed glycan analysis is the UniFi1
biopharmaceutical platform. The UniFi1 platform incorporates
HILIC–UPLC-based glycan separation, fluorescence detection and
online high-resolution mass confirmation, as well as integrated
informatics for glycan identification based on normalized retention
time (expressed as GU values) and accurate mass. The HILIC–UPLC–
MS approach is especially powerful in light of a new N-glycan
labeling reagent, RFMS, which gives up to 160-times higher MS
sensitivity to N-glycans compared with the traditional 2-AB label
[205].Linkage positions
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Symbols
Mannose
α-linkage
β-linkage
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y digestion of N-glycans. In case of ambiguity caused by co-elution of glycan
locks sequentially from the nonreducing (outer) to the reducing (inner) end. The
 movement of chromatographic peaks in response to each of the enzymes, one
. In this figure, we show two IgG-derived N-glycans that showed close retention
hromatogram. The array of enzymes used in this example include: Arthrobacter
cosidase (BKF), b-N-acetylglucosaminidase (GUH). Depending on the specificity
ent of A2G2S1 removed the sialic acid and resulted in forward shift of 0.7 GU
 on top of ABS did not change the glycan profile, thus confirming the absence of
ucture forward by 1.6 GU to the position of A2, which suggested the removal of
o the position for Man3, which suggested the removal of two GlcNAc residues.
ed by the green arrow). Taken together, the exoglycosidase array enables the
quantitative and linkage-specific manner.
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Capillary electrophoresis with laser-induced fluorescence (CE–LIF)
is another powerful technique for analyzing released N-glycans
that are typically labeled with 8-aminopyrene-1,3,6-trisulfonate
(APTS). The separation of the labeled glycans is based on the
charge:hydrodynamic-volume ratio. Similar to HILIC–HPLC/
UPLC, there is an experimental database for normalized retention,
expressed in GU values, of glycan species, for CE–LIF-based ana-
lytical platforms (http://glycobase.nibrt.ie/) [214]. CE–LIF can be
used alone or in conjunction with UPLC as a 2D method [214].
Like UPLC, CE–LIF can be coupled with MS. However, it still
remains a challenge and less explored in the field of glycomics.
A similar technique to CE–LIF is capillary gel electrophoresis with
laser-induced fluorescence (CGE–LIF) based on a DNA sequencer
for APTS-labeled-glycan analysis [215]. This technique is capable of
automated high-throughput glycoprofiling. However, owing to
the lack of a publically available database, assignment of the
glycan structures remains a challenge
Mass spectrometry
The most widely used ionization methods for glycan analysis by
MS are MALDI and ESI. MALDI is a fast and robust method to
characterize and profile neutral glycans. However, MALDI–MS
leads to dissociation of labile glycosidic bonds such as sialic acids,
thus the need for the glycans to be permethylated or the sialic acid
residues derivatized [216]. ESI is a milder ionization method that
can be coupled to online separation methods such as LC. Although
ESI is capable of ionizing native glycans, it still suffers from poor
ionization of the hydrophilic glycans. In many cases, single-stage
mass spectrometry (MS1) cannot confidently assign structures to
glycan-related ions because of ambiguity arising from isobaric and
isomeric structures. MS/MS, using common fragmentation tech-
niques such as CID, can resolve some of the issues but can be
limited in solving some of the structural isomers. However, it has
been shown that the use of low-energy CID on the protonated
adduct of fucosylated N-glycans could lead to misleading fragment
ions, caused by the rearrangement of fucose residues from other
parts of the molecule [196]. Recently, Harvey et al. have shown the
use of negative ion fragmentation provides more structural infor-
mation (e.g. cross-ring fragmentation) as compared with the posi-
tive ion mode without the need to derivatize N-glycans [217,218].
A more recent fragmentation technique, electronic excitation
dissociation (EED), has been implemented to give a more sensitive
and higher-throughput analysis. Yu et al. have demonstrated that
permethylation and labeling of the reducing end, together with
the high resolving power of MS, enabled them to process accu-
rately the complex yet rich structural information from EED
spectra [219]. The use of negative electron transfer dissociation
(NETD) as a fragmentation technique is also very useful for the
analysis of glycosaminoglycans (GAGs), this results in a lower level
of sulfate loss [220]. Advances in nanoflow LC–MS has led to the
development of chip-based technologies (nanoHPLC chip-MS)
that promise faster and more-sensitive glycoprofiling strategies
for the analysis of glycans from monoclonal antibodies [144,221].
Recent publications demonstrate the use of ion mobility separation
as an added dimension to MS (IMS–MS) for separating isobaric N-
glycans from a mixture. The glycans separate on the basis of mass,
charge and shape, determining their unique collisional cross-
section (CCS) [218]. This provides complementary information tothe existing analytical methods. The potential of coupled technol-
ogies, such as LC-IM-MS, in the separation and structural analysis of
complex carbohydrates has already been demonstrated, where the
CCS of glycans and their fragments can be estimated from a set of
calibration data (e.g. a dextran ladder or negatively charged N-
glycans and their fragments) [218,222]. Yamaguchi et al. have
demonstrated the use of 3D methods, for example UPLC-IMS-MS,
to separate pyridylaminated biantennary isomeric N-glycans suc-
cessfully [223], which could also prove to be a valuable tool in future
glycomic studies.
Informatics for glycosylation analysis and pathway
modeling
The development of powerful analytical tools such as CE, HPLC
and MS significantly promoted glycan data accumulation
[204,224]. In response, plenty of software and databases have
emerged to facilitate glycan data analysis. For example, Glycobase
(http://glycobase.nibrt.ie/) documents the experimental analyti-
cal data for a large collection of N- and O-glycans generated from
liquid chromatography and capillary electrophoresis [211]. Uni-
carbDB curates data for glycans analyzed by LC–MS/MS [225].
There are several excellent reviews on currently available software
and databases [212,226–228]. This section does not aim to review
these databases but rather to focus on automated methods for MS-
based glycan and glycopeptide analyses, the latter expected to gain
more importance as a result of new antibody-based fusion protein
drugs that contain multiple N- and O-glycosylation sites [10]. This
will be followed by a review of current methods for glycosylation
pathway modeling and analysis.
Data interpretation of MS-based glycosylation analysis
A multi-institutional study comparing glycan-profiling methods
shows that MS is an efficient method for the characterization of
glycan [229]. However, the automation of MS spectra interpreta-
tion is still a bottleneck in MS-based glycomics projects [230].
Several software platforms have been developed in the past few
years serving this purpose. Here, we summarize some of the
currently available tools on glycan compositional analysis through
MS spectral data.
Database search
Table 3 summarizes the key search engines for glycosylation data
processing based on library matching. GlycoMod is a web tool
designed to find all possible glycan compositions by experiment
mass [231]. It is based on a pre-generated in silico library of glycan
masses. By comparing experiment mass and theoretical mass
stored in the library, GlycoMod returns all compositions under
the same experiment mass. It supports parameter restrictions such
as type of glycan, derivatization and number range for each
monosaccharide and also supports queries on glycopeptides when
the peptide sequence is known. Input experiment masses are
confined to singly charged ions or neutral species and because
of lacking biological filters implausible structures are also included
in the hit list. To avoid giving results with nonbiologically relevant
carbohydrate compositions, GlycosidIQ [232] matches experi-
mental data with theoretical glycofragment mass generated from
GlycoSuiteDB (which is now integrated into UniCarbKB). Mean-
while, GlycoFragment and GlycoSearchMS, a set of web tools
interpreting MS/MS spectra [233,234], has also been developedwww.drugdiscoverytoday.com 757
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TABLE 3
Tools for mass spectrometry (MS)-based glycan analytical data processing based on a library search.
Name Input
MS stage
Databases used for the search Supported
oligosaccharide types
Link
GlycoMod MS In silico glycan database N- and O-linked http://web.expasy.org/glycomod/
GlycosidIQ MS2 A library of theoretical
glycofragment mass generated from
GlycoSuiteDB
N- and O-linked Not maintained
GlycoSearchMS MS2 A library of all possible product ions
for MS/MS data generated from
SweetDB
N- and O-linked http://www.glycosciences.de/sweetdb/
start.php?action=form_ms_search
GlycoPepDB MSn A library of 316 N-linked glycans
reported in the literature
N-linked http://hexose.chem.ku.edu/sugar.php
GlycoSpectrumScan MS A library of all potential
oligosaccharide compositions and a
library of in silico digested peptide
mass of the sample
N- and O-linked Not maintained
Cartoonist MS A library of previously assigned
known structures
N-linked No open access
CartoonistTwo MSn A library of previously assigned
known structures
O-linked No open access
Peptoonist MS1–2 A library of N-glycans generated by
applying same rule as in Cartoonist
and a library of all possible
glycopeptides from sample
N-linked No open access
GlycoPep ID MS2 A library of theoretical m/z values of
all plausible product ions
N-linked http://hexose.chem.ku.edu/
predictiontable.php
GlycoPep Grader (GPG) MS2 A pool of [peptide + core
component] ions calculated from a
list of user input glycopeptide
candidate compositions
N-linked http://glycopro.chem.ku.edu/
GPGHome.php (cannot access now)
GlycoPeptide Search (GPS) MS2 GlycomeDB and a library of in silico
digested peptide mass of user input
protein sequences
N-linked https://edwardslab.bmcb.georgetown.edu/
trac/GlycoPeptideSearch/
GlycoPepDetector MS2 A library of m/z values of c-, z- and y-
ions generated from user input
glycopeptide candidate list
N-linked http://glycopro.chem.ku.edu/ZZKHome.php
(cannot access now)
GlycoMaster DB MS2 A library of N-linked glycans
extracted from GlycomeDB (user
can append their own glycan data)
and a library of in silico digested
peptide mass from user specified
protein sequences
N-linked http://www-novo.cs.uwaterloo.ca:8080/
GlycoMasterDB/
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with a library of theoretical spectra extracted from SweetDB, which
comprises N-linked and O-linked glycans. A similar tool that
searches against carbohydrate databases with glycans reported
in the literature is GlycoPep DB [235]. Together with a library of
potential peptide sequence masses, GlycoSpectrumScan [236]
finds out glycoprotein compositions by analyzing single MS data.
The user needs to input a list of possible oligosaccharide composi-
tions of the sample and a list of peptide masses after in silico
digestion of the sample protein. This software supports analysis
of multiple charged ions, identification of N- and O-linked glyco-
forms and glycan assignment for proteins with multiple site
glycosylation.
Cartoonist is an algorithm that helps to label MALDI–MS peaks
with cartoons for permethylated N-linked oligosaccharides re-
leased from glycoproteins [237]. It matches peaks to potential758 www.drugdiscoverytoday.comglycans by comparing a table of glycans with theoretical mass
and abundance of isotopes. Rather than arbitrarily cutting off the
low intensity peaks, Cartoonist uses isotope envelopes as a filter for
mass matching. Different species have different databases in re-
sponse to restrictions on sample source. Further modifications are
added to enable O-linked oligosaccharide analysis from MS/MS
data [238]. Apart from release glycan analysis, N-glycopeptide
identification is achieved by combing single MS-characterized
N-glycans with MS/MS-identified glycosylated peptides [239].
These programs help to specify oligosaccharide composition but
do not give information concerning the type of bond or the
isomeric oligosaccharide.
Web tools matching against theoretical product ions include
GlycoPep ID, GlycoPep Grader, GlycoPeptideSearch (GPS), Glyco-
Pep Detector and GlycoMaster DB. GlycoPep ID is specialized in
identifying peptide portions from glycoproteins when nonspecific
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plausible product ions for input glycoprotein and compares the
result with CID for a match. No scoring algorithm is included in
this method to screen out the most likely glycopeptide candidate.
GlycoPep Grader [241], another free web tool that helps to deter-
mine glycopeptide composition using MS/MS data, scores glyco-
peptide candidates using CID data in a charge-state-free manner.
GPS is also a program for glycopeptide characterization using CID
data [242]. MS/MS data were screened for glycosylation oxonium
ions at m/z 204 and 366 followed by matching of intact-peptide
fragment ions with an in silico digested peptide list. Glycan struc-
tures are deduced by matching glycan compositions in Glyco-
meDB with the precursor masses after subtraction of previously
identified peptide masses. GlycoPep Detector [243] is a web tool
that targets ETD data analysis. It first generates a library of all
possible fragmentation ions for known glycopeptides and then
assigns a core for each input composition after searching their m/z
value of c-, z- and y-ions against the library. Each time only one
MS/MS spectrum is processed. GlycoMaster DB [244] is software for
processing HCD and ETD spectra when interpreting MS/MS data of
N-linked glycopeptide. It simultaneously searches a library of
glycan structures from GlycomeDB and a library of protein
sequences specified by the user. Besides searching for N-linked
glycopeptide diagnostic peaks, GlycoMaster DB incorporates ion
ladder checks to confirm the glycopeptide spectrum. If ETD data
are provided, separate lists of potential glycans and peptides are
computed independently. Glycopeptides are finally identified by
scoring all pairs of glycan and peptide.
Methods relying on glycan databases are limited by the lack of
comprehensive collections of glycan structures and are insufficient
to discover new glycan structures that have not yet been reported.
Another limitation of performing database searches for glycopro-
tein identification is the need-to-know potential protein
sequences.
De novo sequencing
To discover glycan structures that are not registered in any existing
glycan databases, while avoiding too many implausible structures
being assigned, approaches independent of database search have
been invented to facilitate automatic interpretation of MS data for
released glycans and glycoproteins (Table 4).
STAT is a pioneer software that uses MS/MS data for oligosac-
charide composition analysis [245]. It determines sequence infor-
mation for glycans of up to ten monosaccharide residues. After theTABLE 4
Methods for processing mass spectrometry (MS)-based glycan analy
Name Input MS stage Principles 
STAT MSn Enumerate all possible t
potential compositions 
monosaccharide compo
and precursor m/z spec
GLYCH MS2 Characterize glycan stru
cleavage ions
GlycoPeakfinder MSn Generate all possible com
specified peak list by co
fragmentationuser specifies the monosaccharide component, charge carrier,
precursor and product ion mass, STAT generates all possible topol-
ogies for potential compositions. A rating system is used to list the
most likely structures based on number of bond cleavages. The
limitation of this method is that the user needs to input informa-
tion at each step and the determination of large N-glycans is not
supported. N-glycans containing bisecting GlcNAc are also beyond
its analytical scope.
GLYCH (GlycanCharacterization) is an algorithm for automat-
ed MS/MS glycan identification and characterization [246]. It
utilizes cross-ring fragmentation patterns to derive linkage infor-
mation between monosaccharide residues and distinguishes iso-
meric oligosaccharides from mass spectra. Low-intensity peaks are
removed before processing the spectrum in GLYCH, which might
lead to neglect of the right peaks for glycan structure.
Glyco-Peakfinder is a web application that determines glycan
compositions by de novo annotation of glycan MS spectra [247]. It
enables users to specify possible cross-ring fragments, potential
modifications and charge state. Similar to GlycoFragment, theo-
retically possible fragments of a carbohydrate structure are enu-
merated. The difference is that Glyco-Peakfinder does not depend
on glycan databases with theoretically computed masses or prior
experimentally verified structures. All possible compositions are
computed based on user-defined constraints. Multiple annota-
tions for a single peak would need the user to judge the most
probable structure because no scoring function is applied. Auto-
matic peak detection is not covered so the user has to specify the
monoisotopic m/z values. De novo sequencing tools could be used
to find new structures not reported previously but expert knowl-
edge is required in picking a proper solution to match experimen-
tal data.
Glycosylation pathway analysis
With the growing number of databases accumulating experimen-
tal data of glycan structures, there is a need to link these structures
to our existing knowledge of genes and proteins to understand
complex cellular processes. To associate chemical attributes of
glycans with genomic information, several groups have developed
glycan-related pathway-analysis tools. This section will describe
these resources.
GlycoVis
The main biosynthetic pathways of N-linked glycans have been
well studied in mammalian cells. A relatively small number oftical data based on de novo sequencing.
Limitations
opologies for
calculated after
nent, charge carrier
ified by the user
Confined to glycans with no more than ten
monosaccharide residues; bisecting N-
glycans are not supported
ctures by cross-ring The scoring function is biased toward linear
structure rather than branching structure.
Double cleavage ions are not considered in
the algorithm
positions for a user-
nsidering all types of
No scoring function is applied. User needs to
determine the most probable structure when
single peak gets multiple annotations
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sometimes utilize multiple substrates so that the biosynthetic
pathway is more like a network of 800 or so proteins [248]. Hossler
et al. created a program, called GlycoVis, to visualize the relevant
reaction pathways leading to a distinct N-linked glycan structure.
Distribution of glycan structures on reaction pathways is also
displayed in different colors [249].
Glyco-Net
Glyco-Net is a dynamic functional presentation of relationships
among various biological molecules and biological events. It is part
of Glycoconjugate Data Bank [250]. Besides glycans, biological
molecules like carbohydrate-binding proteins, genes, inhibitors,
lipids and glycosphingolipids are all included. Diseases as well as
biosynthesis are all considered into biological events. External
linkages are also enabled to obtain detailed information of biolog-
ical molecules. Glyco-Net serves as an interface between different
biological databases and dynamically outputs the functional net-
work among biological molecules.
KEGG GLYCAN
KEGG GLYCAN is a nonredundant glycan database that stores
carbohydrate structures that were originally derived from Carb-
Bank [251]. It is a comprehensive glycome informatics resource
integrating knowledge-base of protein networks, genomic infor-
mation and chemical information [252]. This resource includes: (i)
GLYCAN, a database of glycan structures; (ii) glycan-related path-
ways; and (iii) composite structure map (CSM), a tool that illus-
trates all possible variations of carbohydrate structures.
KEGG GLYCAN provides a structural blast tool called KCaM. It
aligns two glycan tree structures and finds the maximum common
braches. It cleans redundant entries obtained from CarbBank and
merges to single entries. Another useful tool in this resource is
KegDraw, it enables querying glycan structures by drawings.
Carbohydrates are synthesized by different types of glycosyl-
transferases. Each enzyme recognizes certain substrates and cata-
lyzes specific biosynthetic reactions. Once the repertoire of
glycosyltransferases is known, the repertoire of glycan structures
can be predicted theoretically (and vice versa). Based on this, CSM
converts genomic glycosyltransferase information into variations
of glycan structures [253].
GlycoVault
GlycoVault is a bioinformatics infrastructure that facilitates visu-
alization, analysis and modeling of glycan pathways [254]. It
supports storage of a variety of data formats using relational
databases and ontologies. Two glycomics analysis tools are includ-
ed: GlycoBrowser and GlyMpse.
GlycoBrowser is a biological pathway visualization tool that
employs graphical representation of glyan structures in the biosyn-
thetic pathways. Like Glycan Builder [255], GlycoBrowser allows
users to build graphic glycan molecules. The difference lies in the
restrictions it enforces using ontology with graphical editing. If
experimental data or relevant information are present, GlycoBrow-
ser will overlay experimental data with the displayed pathway.
GlyMpse is an ontology-driven simulation tool that models
biochemical pathways. Biochemical entities such as glycans and
enzymes are represented as nodes and enzymatic reactions as
edges. Simulation datasets comprise metabolic pathways and en-
zyme kinetics datasets. Pathway simulation is based on firing
delays and enzyme concentrations.760 www.drugdiscoverytoday.comGlycan Pathway Predictor (RINGS)
As a part of the resource for informatics of glycomes at Soka
(RINGS), Glycan Pathway Predictor (GPP) is a web-based tool that
models specified glycans with substrate specificity rules [256]. It
implements the mathematical model of N-glycosylation devel-
oped by Krambeck et al. [146,147]. GPP can be used to generate
potential glycans catalyzed by a select set of glyco-enzymes to-
gether with detailed pathways and corresponding enzymes. Tak-
ing any glycan structure as an entry point, GPP will retrieve a
possible glycan synthesis pathway map with a selected glyco-
enzyme set.
GPP utilizes KEGG Chemical Function (KCF) format as the input
for glycan structures but enables multiple output formats by using
LinerCode1. Free from the requirements of detailed concentration
information of substrates, GPP does not support enzyme kinetic
simulations. If the enzyme set is not well picked or the input
format is wrong, GPP might fail to return any result.
Experimental implementation of glycosylation pathway analysis
Glycosylation pathway analysis is based on information of glycan
structures, glycosyltransferases, glycosidases and other glycan-
binding molecules. New experimental technologies accelerate
the accumulation of such fundamental knowledge. A medium-
throughput quantitative, real-time reverse-transcriptase PCR
(qRT-PCR) platform now allows the verification of glycomic path-
way models that associate changes in glycan abundance and gene
expression level for corresponding biosynthesis enzymes [248].
Recent development of high-throughput HPLC/UPLC technolo-
gies facilitates straightforward glycan analysis and enriches the
knowledge-base of glycan structures [210]. Advances in genotyp-
ing technologies now permit identifying and validating millions
of new single nucleotide polymorphisms (SNPs), which further
enables hypothesis-free genome-wide association studies (GWAS)
[257]. A GWAS study that combines high-throughput glycomics
analysis discovered that HNF1 and its downstream target HNF4
play an important part in key fucosyltransferase and fucose bio-
synthetic gene regulation [213]. A more recent GWAS study iden-
tified five genes that have no prior report on their participation in
protein glycosylation to be strongly associated with IgG N-glyco-
sylation and autoimmune diseases [14]. With more pieces of
information added into our knowledge-base, glycomic pathway
analysis would be more informative and would give better guid-
ance in new discoveries and provide better ways of controlling the
cellular pathways in bioprocessing.
Concluding remarks
The biopharmaceutical industry has experienced tremendous
growth during the past two decades [12]. mAbs provide a major
driving force in this development. The industry will be further
propelled by the rise of biosimilars [10]. The cost of goods for
therapeutic mAbs has dropped significantly over the years because
of advancements in the cell culture processes [91]. In addition,
guidelines for regulating the biosimilars have placed an emphasis
on glycosylation analysis and comparability [79,83]. Therefore,
one major challenge in successfully developing therapeutic mAbs
lies in controlling glycosylation. Glycosylation will play an even
more important part in the light of biobetter drugs [258]. Produc-
ing optimal and consistent glycosylation requires an integrated
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trated on empirical adjustments of upstream cell culture param-
eters. With the accumulation of knowledge and development of
new tools, we see opportunities in the following areas: (i) custom-
making glycoforms by editing the glycosylation machinery of the
host cells; (ii) development of online and atline analytical tech-
nologies to monitor and adjust the process continuously; (iii) the
effective application of QbD and PATs in real-time monitoring
and controlling of glycosylation; (iv) glycoform-specific down-
stream purification strategies; (v) integrated informatics plat-
forms for data processing and model-driven glycosylation
predictions; and (vi) systems biology of molecular and cellular
events in the cell culture. An integrated approach combining thecapabilities of the above areas will truly enable the industry to
harness glycosylation for successful biopharmaceutical drug de-
velopment.
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